SLEEP CONNECT powered by COR2ED(@SleepConnect_):Patients with narcolepsy type 1 continue to experience residual disease burden despite guideline-recommended therapy However, orexin-targeted therapies are showing promising results in trials... 📈 >> Selective hypocretin receptor agonists, designed to directly restore orexin signalling << 📺 Sleep Medicine expert, Prof. Yves Dauvilliers takes us through the evolution of narcolepsy type 1 care in this case-based animated video Programme endorsed by ANC & Reference Centre for Narcolepsy and Rare Hypersomnias Supported by an Independent Educational Grant from Takeda

SLEEP CONNECT powered by COR2ED@SleepConnect_

2026.10.01 07:39

Patients with narcolepsy type 1 continue to experience residual disease burden despite guideline-recommended therapy However, orexin-targeted therapies are showing promising results in trials... 📈 >> Selective hypocretin receptor agonists, designed to directly restore orexin signalling << 📺 Sleep Medicine expert, Prof. Yves Dauvilliers takes us through the evolution of narcolepsy type 1 care in this case-based animated video Programme endorsed by ANC & Reference Centre for Narcolepsy and Rare Hypersomnias Supported by an Independent Educational Grant from Takeda